Two-year follow-up of thirty-two non-functional benign adrenal incidentalomas

Abstract

Objective: To evaluate the risk of developing endocrine hyperactivity and carcinoma during a period of up to 5 yr in patients with apparently benign and non-functioning adrenal incidentalomas. Patients and methods: Thirty-two patients (mean age: 57.0±8.3 yr) were investigated in a prospective follow-up study for a median time of 24 months. Twentyeight patients had unilateral and 4 had bilateral masses. Initial avarage mass diameter was 17.47±6.60 mm. All patients were followed up yearly by physical examination, metabolic parameters, hormonal evaluation [morning cortisol after 3-mg dexamethasone suppression, urinary metanephrines, and upright aldosterone/plasma renin activity (PRA)]. Results: Among the clinical characteristics, 48% of patients were obese, 20% were hypertensive, 13 had Type 2 diabetes and impaired glucose tolerance. During follow-up period no significant change in the functional status was observed and no malignant transformation occured. Only 1 patient developed subclinical Cushing’s syndrome at the end of the 1st year and referred to surgery. Change in mass size was correlated with homeostasis model assessment of insulin resistance (p=0.002), upright aldosterone/PRA (p=0.041), cortisol after dexamethasone suppression (p=0.048) and 24-h urinary normetanephrine (p=0.005) levels. Gender, body mass index, glucose metabolism, and blood pressure were not found to be correlated with change in mass size and functional status. Conclusions: Due to the extremely low risk of developing malignancy during up to 5 yr of follow-up, conservative approach for the management of adrenal incidentalomas is thought to be appropriate. However, possibility of evolution to hormonal hypersecretion makes long-term follow-up of 2-to-5 yr seems to be obligatory.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR The clinically inapperant adrenal mass: update in diagnosis and management. Endocr Rev 2004, 25: 309–40.

    PubMed  Article  Google Scholar 

  2. 2.

    Libè R, Dall’Asta C, Barbetta L, Baccarelli A, Beck-Peccoz P, Ambrosi B. Long-term follow-up study of patients with adrenal incidentalomas. Europen J of Endocrinol 2002, 147: 489–94.

    Article  Google Scholar 

  3. 3.

    Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B. Incidentally discovered adrenal masses. Endocr Rev 1995, 16: 460–84.

    PubMed  CAS  Google Scholar 

  4. 4.

    Gross MD, Shapiro B. Clinically silent adrenal masses. J Clinic Endocrinol Metab 1993, 77: 885–8.

    CAS  Google Scholar 

  5. 5.

    Bülow B, Jansson S, Juhlin C. Adrenal incidentaloma-follow-up results from a Swedish prospective study. Eur J Endocrinol 2006, 154: 419–23.

    PubMed  Article  CAS  Google Scholar 

  6. 6.

    Grossrubatscher E, Vignati F, Possa M, Lohi P. The natural history of incidentally discovered adrenocortical adenomas: A retrospective evaluation. J Endocrinol Invest 2001, 24: 846–55.

    PubMed  Article  CAS  Google Scholar 

  7. 7.

    Barzon L, Scaroni C, Sonino N, Fallo F, Paoletta A, Boscaro M. Risk factors and long-term follow-up of adrenal incidentalomas. J Clinic Endocrinol Metab 1999, 84: 520–6.

    CAS  Google Scholar 

  8. 8.

    Reincke M Subclinical Cushing’s syndrome. Endocrinol Metab Clin North Am 2000, 29: 43–56.

    Article  Google Scholar 

  9. 9.

    Linos DA. Management approaches to adrenal incidentalomas(adrenalomas). A view from Athens, Greece. Endocrinol Metab Clin North Am 2000, 29: 141–57.

    PubMed  Article  CAS  Google Scholar 

  10. 10.

    Vilar L, Freitas Mda C, Canadas V, et al. Adrenal incidentalomas: Diagnostic evaluation and long-term follow-up. Endocr Pract 2008, 14: 269–78.

    PubMed  Article  Google Scholar 

  11. 11.

    Grumbach MM, Biller BM, Braunstein GD, et al. Management of the clinically inapperant adrenal mass (“incidentaloma”). Ann Intern Med 2003, 138: 424–9.

    PubMed  Article  Google Scholar 

  12. 12.

    Mantero F, Arnaldi G 2000 Management approaches to adrenal incidentalomas. Endocrinol Metab Clin North Am 29: 107–25.

    PubMed  Article  CAS  Google Scholar 

  13. 13.

    Sirén J, Tervahartiala P, Sivula A, Haapiainen R. Natural course of adrenal incidentalomas: seven-year follow-up study. World J Surg 2000, 24: 579–82.

    PubMed  Article  Google Scholar 

  14. 14.

    Sirén JE, Haapiainen RK, Huikuri KT, Sivula AH. Incidentalomas of the adrenal gland: 36 operated patients and review of the literature. World J Surg 1993, 17: 634–9.

    PubMed  Article  Google Scholar 

  15. 15.

    Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. J Clinic Endocrinol Metab 2000, 85: 637–44.

    CAS  Google Scholar 

  16. 16.

    Bernini GP, Moretti A, Oriandini C, Bardini M, Taurino C, Salvetti A. Long-term morphological and hormonal follow-up in a single unit on 115 patients with adrenal incidentalomas. British J Cancer 2005, 92: 1104–9.

    Article  CAS  Google Scholar 

  17. 17.

    Jockenhövel F, Kuck W, Hauffa B, et al. Conservative and surgical management of incidentally discovered adrenal tumors. J Endocrinol Invest 1992, 15: 331–7.

    PubMed  Article  Google Scholar 

  18. 18.

    Barzon L, Sonino N, Fallo F, Palu G, Boscaro M. Prevelance and natural history of adrenal incidentalomas. Eur J Endocrinol 2003, 149: 273–85.

    PubMed  Article  CAS  Google Scholar 

  19. 19.

    Rossi R, Tauchmanova L, Luciano A, et al. Subclinical Cushing’s syndrome in patients with adrenal incidentaloma: Clinical and biochemical features. J Clin Endocrinol Metab 2000, 85: 1440–8.

    PubMed  CAS  Google Scholar 

  20. 20.

    Valli N, Catargi B, Ronci N, et al Biochemical screening for subclinical cortisol-secreting adenomas amongst adrenal incidentalomas. Europen J Endocrinol 2001, 144: 401–8.

    Article  CAS  Google Scholar 

  21. 21.

    Eldeiry LS, Garber JR Adrenal incidentalomas, 2003 to 2005: Experience after publication of the National Institutes of Health Consensus Statement. Endocr Pract 2008, 14: 279–84.

    PubMed  Article  Google Scholar 

  22. 22.

    Tsagarakis S, Vassiliadi D, Thalassinos N. Endogenous subclinical hypercortisolism: Diagnostic uncertanities and clinical implications. J Endocrinol Invest 2006, 29: 471–82.

    PubMed  Article  CAS  Google Scholar 

  23. 23.

    Garrapa G, Pantanetti P, Arnaldi G, Mantero F, Faloia E. Body composition and metabolic features in women with adrenal incidentaloma or Cushing’s syndrome. J Clinic Endocrinol Metab 2001, 86: 5301–6.

    CAS  Google Scholar 

  24. 24.

    Terzolo M, Pia A, Alì A, et al. Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clinic Endocrinol Metab 2002, 87: 998–1003.

    Article  CAS  Google Scholar 

  25. 25.

    Reincke M, Fassnacht M, Väth S, Mora P, Allolio B. Adrenal incidentalomas: a manifestation of the metabolic syndrome? Endocrine Research 1996, 22: 757–61.

    PubMed  CAS  Google Scholar 

  26. 26.

    Singh PK, Bush HN. Adrenal insidentaloma: evaluation and management. J Clin Pathol 2008, 61: 1168–73.

    PubMed  Article  CAS  Google Scholar 

  27. 27.

    Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing’s Syndrome: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008, 93: 1526–40.

    PubMed Central  PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to H. Yılmaz.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Yılmaz, H., Tütüncü, N.B. & Şahin, M. Two-year follow-up of thirty-two non-functional benign adrenal incidentalomas. J Endocrinol Invest 32, 913–916 (2009). https://doi.org/10.1007/BF03345772

Download citation

Keywords

  • Adrenal incidentaloma
  • insulin resistance
  • subclinical Cushing’s syndrome